| Drug Name |
Riociguat |
| Drug ID |
BADD_D01948 |
| Description |
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. |
| Indications and Usage |
Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%). |
| Marketing Status |
Prescription |
| ATC Code |
C02KX05 |
| DrugBank ID |
DB08931
|
| KEGG ID |
D09572
|
| MeSH ID |
C542595
|
| PubChem ID |
11304743
|
| TTD Drug ID |
D04UKC
|
| NDC Product Code |
50419-251; 50419-250; 12527-0253; 69766-021; 12527-0254; 12527-0251; 46708-894; 50419-253; 12527-0250; 50419-254; 50419-252; 12527-0252 |
| Synonyms |
riociguat | BAY 63-2521 | BAY-63-2521 | Adempas |
